INSR and renal cell carcinoma: To state clinical relevance, we have previously shown that in RCC patients angiogenesis is clearly inhibited in the primary tumour in response to sunitinib treatment and demonstrated that this treatment led to normalisation of angiogenic growth factor expression.24 We now show that, in analogy to VEGFRs, INSR is also suppressed by angiostatic treatment with sunitinib.